Fungal Necrotizing Otitis Externa: Three Key Clinical Questions Answered

Fungal necrotizing otitis externa, a rare but potentially life-threatening infection that can extend from the external ear canal into the skull base, is frequently difficult to identify in its early stages. A systematic analysis published in Eye & ENT Research highlights the warning signs that should prompt clinicians to consider a fungal cause when standard antibiotic treatment fails. The study also examines antifungal selection, treatment duration, diagnostic testing and the need for coordinated specialist care.

Necrotizing otitis externa, sometimes called malignant otitis externa, typically begins as an infection of the skin lining the external auditory canal. In severe cases, the infection can spread into adjacent bone and deeper tissues, producing osteomyelitis at the skull base. Although bacterial organisms, particularly Pseudomonas aeruginosa, are classically associated with the disease, fungal pathogens can cause a similar and more difficult-to-treat condition. Delayed recognition may allow the infection to progress toward the temporomandibular joint, cranial nerves and central nervous system.

According to the literature analysis, fungal necrotizing otitis externa should be suspected when a patient shows no improvement, or continues to deteriorate, after three to four weeks of antibiotic therapy. Repeated ear swabs that fail to identify a bacterial or fungal organism provide another important warning signal. The researchers emphasize that negative swab results do not reliably exclude fungal disease, because many fungal species are located in deeper infected tissue and may not grow in routine cultures obtained from the ear canal.

For this reason, tissue biopsy or bone biopsy may be necessary for an early and definitive diagnosis. Sampling infected tissue can allow laboratories to perform histopathological examination, fungal culture and molecular or other species-identification tests. These procedures may distinguish invasive fungal infection from persistent superficial inflammation and can provide information needed to select an effective antifungal drug. The analysis stresses that diagnosis should not rely solely on initial swab cultures when clinical deterioration continues.

Signs of advanced disease require particularly urgent evaluation. Facial nerve paralysis suggests that the infection has extended beyond the external ear canal and is affecting structures at the skull base. Bilateral disease may indicate extensive or unusual infection, while radiologic evidence of temporomandibular joint destruction points to invasive bony involvement. In such circumstances, the authors recommend prompt initiation of antifungal treatment while diagnostic investigations continue, rather than waiting indefinitely for conventional culture results.

Voriconazole was the most frequently reported antifungal in the reviewed literature, appearing in 22 of the 32 studies analyzed. The drug is often favored because it achieves strong penetration into bone and the central nervous system, areas that may be involved when necrotizing otitis externa becomes invasive. Compared with amphotericin B, voriconazole is also generally associated with less nephrotoxicity. These pharmacological advantages make it an important option for infections that extend toward the skull base or intracranial structures.

Voriconazole is not universally effective, however, and its use requires careful monitoring. Potential problems include liver toxicity, clinically significant drug interactions and the emergence of resistance. The analysis specifically identifies Scedosporium apiospermum as an organism that may be difficult to treat and may require combination antifungal therapy. Because antifungal susceptibility varies between species, the researchers argue that accurate pathogen identification and susceptibility testing should guide treatment whenever possible.

Treatment commonly continues for a prolonged period. Across the studies reviewed, the mean duration of antifungal therapy was 14.7 weeks, and the authors recommend a minimum course of 12 weeks. Patients with extensive bone involvement, cranial nerve complications, persistent infection or difficult-to-treat organisms may require substantially longer therapy. Clinical improvement alone may not be sufficient to determine whether treatment can stop, making repeated imaging, laboratory assessment and specialist review important components of follow-up.

The analysis also describes fungal necrotizing otitis externa as a condition that requires multidisciplinary management rather than a single intervention. Ear, nose and throat specialists, infectious-disease physicians, radiologists, microbiologists and, when necessary, neurologists or surgeons may all contribute to care. Regular aural toileting can help remove infected debris, while repeated swabs, biopsies and imaging can provide information about microbiological response and the resolution of bone disease. The authors caution that current recommendations are based mainly on case reports and retrospective studies, not prospective clinical trials, so formal evidence-based guidelines remain to be established.

The work, titled “An Update on the Current Practice on the Management of Fungal Necrotizing Otitis Externa: A Systematic Analysis of the Literature,” was published in Eye & ENT Research on June 27, 2026. Its findings underline the importance of reconsidering the diagnosis when prolonged antibiotic therapy fails and cultures remain negative. Early tissue-based diagnosis, rapid recognition of invasive features and species-directed antifungal treatment could help clinicians manage a rare infection whose consequences can extend far beyond the ear.

News Publication Date: 27-Jun-2026

Web References: https://doi.org/10.1002/eer3.70042

References: Eye & ENT Research, DOI: 10.1002/eer3.70042